Abstract
Ivermectin, a US Food and Drug Administration-approved anti-parasitic agent, was found to inhibit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication in vitro. A randomized, double-blind, placebo-controlled trial was conducted to determine the rapidity of viral clearance and safety of ivermectin among adult SARS-CoV-2 patients. The trial included 72 hospitalized patients in Dhaka, Bangladesh, who were assigned to one of three groups: oral ivermectin alone (12 mg once daily for 5 days), oral ivermectin in combination with doxycycline (12 mg ivermectin single dose and 200 mg doxycycline on day 1, followed by 100 mg every 12 h for the next 4 days), and a placebo control group. Clinical symptoms of fever, cough, and sore throat were comparable among the three groups. Virological clearance was earlier in the 5-day ivermectin treatment arm when compared to the placebo group (9.7 days vs 12.7 days; p = 0.02), but this was not the case for the ivermectin + doxycycline arm (11.5 days; p = 0.27). There were no severe adverse drug events recorded in the study. A 5-day course of ivermectin was found to be safe and effective in treating adult patients with mild COVID-19. Larger trials will be needed to confirm these preliminary findings.
Keywords: Bangladesh; COVID-19; Doxycycline; Ivermectin; SARS-CoV-2.
【저자키워드】 COVID-19, Ivermectin, SARS-CoV-2, Bangladesh, doxycycline, 【초록키워드】 coronavirus, Trial, Symptom, drug, in vitro, cough, viral clearance, Replication, Randomized, clinical, Fever, placebo-controlled trial, Patient, Mild, Placebo, single dose, SARS-CoV-2 patients, food, Combination, Safe, double-blind, sore throat, acute respiratory syndrome, control group, ivermectin treatment, three groups, clearance, preliminary findings, effective, event, Course, inhibit, conducted, determine, hospitalized patient, comparable, assigned, recorded, anti-parasitic, the placebo group, 【제목키워드】 Treatment, Course, reduce, duration of illness,